Topics
Glioblastoma | Treatment | Side effects | Temozolomide
Home > Publications > Topics > Glioblastoma > Treatment > Side effects > Temozolomide
Yu Y, Hou X, Xu K.
A multi-database
pharmacovigilance study reveals distinctive immunosuppressive and
opportunistic infection disproportionality signals with
bevacizumab and temozolomide combination therapy in glioblastoma.
Front
Med (Lausanne). 2026 Mar 11;13:1773599. doi:
10.3389/fmed.2026.1773599. PMID:
41889512. ˍ